Menu

Medical

Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C

Once-Daily Combination Achieves High SVR12 Rates Across Multiple HCV Genotypes BOSTON–(BUSINESS WIRE)–Nov. 11, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced data from three Phase 2 open-label studies evaluating the safety and efficacy of an investigational all-oral pan-genotypic regimen containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved as Sovaldi® by the U.S. Food and Drug […]

Gilead Announces Harvoni Study Results in Chronic Hepatitis C Patients with Advanced Liver Disease and Those Who Failed Prior Treatment

, , ,

High Cure Rates in Nearly 800 HCV Patients with Advanced Liver Disease BOSTON–(BUSINESS WIRE)–Nov. 11, 2014– Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from several Phase 2 and Phase 3 studies evaluating investigational uses of Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) for the treatment of chronic hepatitis C virus (HCV) infection in patients with […]

SpendWell Health announces its participation in the upcoming 2014 IHC FORUM West conference

,

ATLANTA, NOVEMBER 10, 2014 -– SpendWell Health™ – part of the Cambia Health Solutions group – will be highlighting their innovative online marketplace at the 2014 IHC FORUM West conference taking place November 10-12, 2014 at the Red Rock Resort Spa & Casino in Las Vegas. SpendWell’s online marketplace helps employees with high-deductible health plans […]

FDA Accepts Amgen’s Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab

, ,

THOUSAND OAKS, Calif., Nov. 10, 2014 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen’s Biologics License Application (BLA) for evolocumab for the treatment of high cholesterol. Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a […]

Interim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting®

, ,

Merck Plans to Initiate Phase 2 C-CREST Program to Evaluate Merck’s Triple Combination of Grazoprevir/Elbasvir with MK-3682 (formerly IDX21437), a Novel Nucleotide Inhibitor, in Q1 2015 BOSTON, November 9, 2014–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential […]

New Studies Investigating the Use of KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time

, , ,

By Year End, Data on KEYTRUDA in Seven Tumor Types Will Have Been Presented WHITEHOUSE STATION, N.J., November 6, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA® (pembrolizumab) – the […]

Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014

,

Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company’s Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that more than 50 abstracts from the Company’s oncology and […]

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV

, , ,

High Rates of Viral Suppression and Improved Renal and Bone Safety Demonstrated in Phase 3 Studies First of Several TAF-Based Single Tablet Regimens Being Evaluated by Gilead FOSTER CITY, Calif.–(BUSINESS WIRE)–Nov. 6, 2014– Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug […]

North Wales first in Europe to connect cardiology departments with GE Healthcare’s Centricity Cardio Enterprise solution

, ,

GE Healthcare supporting a number of European hospitals to improve efficiency and patient-care via innovative integrated care solutions Birmingham, 4 November 2014 – GE Healthcare is sharing information on several partnerships focusing on integrated care at EHI Live on the 4-5 November in Birmingham, UK. In North Wales, Betsi Cadwaladr University Health Board is to […]

Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer

, ,

Study Failed to Meet Secondary Endpoint of Overall Survival THOUSAND OAKS, Calif., Nov. 4, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the top-line secondary endpoint results of overall survival from the Phase 3 TRINOVA-1 trial in women with recurrent platinum-resistant ovarian cancer. The study, which evaluated trebananib plus paclitaxel versus placebo plus paclitaxel, did not […]

«‹ 8 9 10 11›»